Michael J. McElhaugh - 20 Jan 2022 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Chief Business Officer
Signature
/s/ David C. Hastings as attorney-in-fact for Michael J. McElhaugh
Issuer symbol
ABUS
Transactions as of
20 Jan 2022
Net transactions value
+$915,638
Form type
4
Filing time
20 Jan 2022, 16:53:50 UTC
Next filing
03 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $915,638 +325,850 $2.81 325,850 20 Jan 2022 Common Shares 325,850 $2.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options will vest and become exercisable 1/48th each month over the four year period.